6.5 References

(Hyperlinks to references in text)

  1. Baumann M et al. Radiation oncology in the era of precision medicine. Nat. Rev. Cancer 2016;16(4):234–249.
  2. Begg AC, Stewart F a, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011;11(4):239–253.
  3. Grégoire V, Jeraj R, Lee JA, O’Sullivan B. Radiotherapy for head and neck tumours in 2012 and beyond: Conformal, tailored, and adaptive?. Lancet Oncol. 2012;13(7):e292–e300.
  4. van de Vijver MJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002;347(25):1999–2009.
  5. van ’t Veer LJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415(6871):530–536.
  6. Ginos M a et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 2004;64(1):55–63.
  7. Chung CH et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006;66(16):8210–8.
  8. Giri U et al. Molecular signatures associated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgery and radiation. Int. J. Radiat. Oncol. Biol. Phys. 2006;64(3):670–7.
  9. Ganly I et al. Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. J. Clin. Oncol. 2007;25(11):1369–76.
  10. Pramana J et al. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007;69(5):1544–52.
  11. Dumur CI et al. Genes involved in radiation therapy response in head and neck cancers. Laryngoscope 2009;119(1):91–101.
  12. Méndez E et al. A genetic expression profile associated with oral cancer identifies a group of patients at high risk of poor survival. Clin. cancer Res. 2009;15(4):1353–61.
  13. Linge A et al. Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV(-) HNSCC after postoperative radiochemotherapy: A multicenter study of the DKTK-ROG. Clin. Cancer Res. 2016;22(11):2639–2649.
  14. Baschnagel AM et al. Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas. J. Oral Pathol. Med. [published online ahead of print: 2016];(248). doi:10.1111/jop.12478
  15. Aso T et al. Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and worsens the prognosis of patients with advanced head and neck cancer. PLoS One 2015;10(3):1–14.
  16. Chen J et al. Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. BMC Cancer 2014;14:15.
  17. Näsman A et al. Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival. Cancer Med. 2013;2(4):507–18.
  18. Lindquist D, Ährlund-richter A, Tarján M, Tot T, Dalianis T. Intense CD44 Expression Is a Negative Prognostic Factor in Tonsillar and Base of Tongue Cancer2012;162:153–161.
  19. Kokko L-L et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 2011;47(6):510–6.
  20. Björk-Eriksson T, West C, Karlsson E, Mercke C. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 2000;46(1):13–9.
  21. Lu J et al. MicroRNA expression profiles classify human cancers. Nature 2005;435(7043):834–8.
  22. Latil M et al. Cell-Type-Specific Chromatin States Differentially Prime Squamous Cell Carcinoma Tumor-Initiating Cells for Epithelial to Mesenchymal Transition. Cell Stem Cell 2016;1–14.
  23. Ghuwalewala S et al. CD44 high CD24 low molecular signature determines the Cancer Stem Cell and EMT phenotype in Oral Squamous Cell Carcinoma. Stem Cell Res. 2016;16(2):405–417.
  24. Mani S a et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133(4):704–15.
  25. Polyak K, Weinberg R a. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009;9(4):265–73.
  26. Wellner U et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009;11(12):1487–95.
  27. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29(34):4741–51.
  28. Voon DC-C et al. EMT-induced stemness and tumorigenicity are fueled by the EGFR/Ras pathway. PLoS One 2013;8(8):e70427.
  29. Gemenetzidis E, Gammon L, Biddle A, Emich H, Ic M. Invasive oral cancer stem cells display resistance to ionising radiation. Oncotarget 2014;6(41). doi:10.18632/oncotarget.6268
  30. Kinugasa H et al. Mitochondrial SOD2 regulates epithelial–mesenchymal transition and cell populations defined by differential CD44 expression. Oncogene 2015;34(August 2014):1–11.
  31. Liu S et al. G9a is essential for EMT-mediated metastasis and maintenance of cancer stem cell-like characters in head and neck squamous cell carcinoma. Oncotarget 2015;6(9). doi:10.18632/oncotarget.3159
  32. Gammon L, Biddle A, Heywood HK, Johannessen AC, Mackenzie IC. Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism. PLoS One 2013;8(4):e62493.
  33. Preca BT et al. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int. J. Cancer 2015;137(11):2566–2577.
  34. La Fleur L, Johansson A-C, Roberg K. A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PLoS One 2012;7(9):e44071.
  35. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics 1983;39(2):499–503.
  36. Linge A et al. Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. Clin. Transl. Radiat. Oncol. 2016;1:19–26.
  37. Hanns E et al. Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature. Oral Oncol. 2015;51(9):848–856.
  38. Sørensen BS et al. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. Radiother. Oncol. 2013;108(3):500–5.
  39. Hayes DN, Van Waes C, Seiwert TY. Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors. J. Clin. Oncol. 2015;33(29):3227–3234.
  40. Güster JD et al. The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines. Radiother. Oncol. 2014;113(3):345–351.
  41. Kong CS et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 2009;74(2):553–61.
  42. Mayer A, Zahnreich S. Downregulation of EGFR in hypoxic , diffusion-limited areas of squamous cell carcinomas of the head and neck. Br. J. Cancer 2016;115(August):1351–1358.
  43. Boeckx C et al. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines. BMC Res. Notes 2015;8(1):203.
  44. Krause M et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother. Oncol. 2005;76(2):162–167.
  45. Pedicini P et al. Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat. Oncol. 2012;7(1):143.
  46. Lefevre M et al. Epithelial to mesenchymal transition and HPV infection in squamous cell oropharyngeal carcinomas: the papillophar study. Br. J. Cancer 2017;116(3):362–369.
  47. Peinado H, Cano A. A hypoxic twist in metastasis. Nat. Cell Biol. 2008;10(3):253–4.
  48. Yang M-H et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 2008;10(3):295–305.
  49. Yang M, Wu K. TWIST activation by hypoxia inducible factor-1 (HIF-1). Cell Cycle 2008;1(July):2090–2096.
  50. Byers LA et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 2013;19(1):279–90.
  51. Holz C et al. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. Radiother. Oncol. 2011;101(1):158–64.
  52. Rieckmann T et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother. Oncol. 2013;107(2):242–246.
  53. Bristow RG, Hill RP. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 2008;8(3):180–92.
  54. Boohaker RRJR, Cui X, Stackhouse M, Xu B. ATM-mediated Snail Serine 100 phosphorylation regulates cellular radiosensitivity. Radiother. Oncol. 2013;231(3):403–408.
  55. Schaaf MBE et al. The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia. Radiother. Oncol. 2013;108(3):529–534.
  56. Huang Q et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 2011;17(7):860–866.
  57. Rietbergen MM et al. Cancer stem cell enrichment marker CD98: a prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur. J. Cancer 2014;50(4):765–73.
  58. Bittner M-I et al. Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy. Acta Oncol. (Madr). 2016;55(11):1299–1304.
  59. Das B et al. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008;26(7):1818–30.
  60. Heddleston JM et al. Hypoxia inducible factors in cancer stem cells. Br. J. Cancer 2010;102(5):789–95.
  61. Krishnamachary B et al. Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS One 2012;7(8):e44078.
  62. Van Den Beucken T et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat. Commun. 2014;5:5203.
  63. Perez A et al. CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression. Oral Oncol. 2013;49(4):306–13.
  64. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 2006;98(24):1777–85.
  65. Harris IS et al. Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. Cancer Cell 2015;27(2):211–222.
  66. Diehn M et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458(7239):780–3.
  67. Bao S et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444(7120):756–60.
  68. Gieni RS, Ismail IH, Campbell S, Hendzel MJ. Polycomb group proteins in the DNA damage response: A link between radiation resistance and “stemness”. Cell Cycle 2011;10(6):883–894.
  69. Brown JM. Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. Br. J. Radiol. 2014;87:20130686.
  70. Shenoy AK et al. Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. J. Clin. Invest. 2016;126(11):4174–4186.
  71. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 2008;26(17):2839–45.
  72. Ward MJ et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br. J. Cancer 2014;110(2):489–500.
  73. Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress : obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 2016;36(May):1–7.
  74. Su S et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014;25(5):605–20.
  75. Cui Y-H et al. Radiation promotes invasiveness of non-small-cell lung cancer cells through granulocyte-colony-stimulating factor. Oncogene 2015;34(November 2014):1–11.
  76. Chen L et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun. 2014;5:5241.
  77. Akalay I et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from t-cell-mediated lysis. Cancer Res. 2013;73(8):2418–27.
  78. Matsuoka Y et al. IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma. Br. J. Cancer 2016;115(10):1234–1244.
  79. Zegers CML et al. Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects. Clin. Cancer Res. 2014;2(23). doi:10.1158/1078-0432.CCR-14-2676
  80. Nakazawa MS, Keith B, Simon MC. Oxygen availability and metabolic adaptations. Nat. Rev. Cancer 2016;16(10):663–73.
  81. Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism. Br. J. Cancer 2016;114(12):1305–1312.
  82. Ballman K V. Biomarker: Predictive or prognostic?. J. Clin. Oncol. 2015;33(33):3968–3971.
  83. Eriksen JG, Steiniche T, Overgaard J. The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol. (Madr). 2005;44(1):50–8.
  84. Bentzen SM et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J. Clin. Oncol. 2005;23(24):5560–7.
  85. Toustrup K, Sørensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin. Radiat. Oncol. 2012;22(2):119–27.
  86. Thomson D et al. NIMRAD – a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin. Oncol. 2014;26(6):344–7.
  87. Bossi P et al. Functional genomics uncover the biology behind the responsiveness of head and neck squamous cell cancer patients to cetuximab. Clin. Cancer Res. 2016;22(15):3961–3970.
  88. Chau NG, Hammerman PS. Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon. Clin. cancer Res. 2016;22(15):3710–2.
  89. Alizadeh A a et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 2015;21(8):846–853.
  90. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 2013;108(3):479–85.
  91. Toustrup K et al. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. Acta Oncol. (Madr). 2016;(May):1–8.
  92. Roepman P et al. Dissection of a metastatic gene expression signature into distinct components. Genome Biol. 2006;7(12):R117.
  93. Winter SC et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007;67(7):3441–9.
  94. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. (Madr). 1988;27(2):131–46.
  95. Bussink J, van Herpen CML, Kaanders JH a M, Oyen WJG. PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol. 2010;11(7):661–9.
  96. Hoeben B a W, Bussink J, Troost EGC, Oyen WJG, Kaanders JH a M. Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta Oncol. (Madr). 2013;52(7):1257–71.
  97. Hoeben B a W et al. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J. Nucl. Med. 2013;54(4):532–40.
  98. Bollineni VR et al. Dynamics of tumor hypoxia assessed by (18)F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies. Radiother. Oncol. 2014;113(2):198–203.
  99. Min M et al. Prognostic role of metabolic parameters of 18F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2015;42(13):1984–1994.
  100. Jentsch C et al. Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. Radiother. Oncol. 2016;121(3):447–452.
  101. Carvalho S et al. Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – A survival model with external validation. Radiother. Oncol. 2015;119(3):487–494.
  102. Turajlic S, Swanton C. Tracking tumour evolution through liquid biopsy. Nat. Rev. Clin. Oncol. 2015;12(10):565–566.
  103. Franzmann EJ et al. Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck 2012;34(5):687–95.
  104. Satelli a. et al. Epithelial-Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression. Clin. Cancer Res. 2014;899–907.
  105. Jung AC et al. A poor prognosis subtype of HNSCC is consistently observed across methylome, transcriptome, and miRNome analysis. Clin. Cancer Res. 2013;19(15):4174–4184.
  106. Rupaimoole R et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat. Commun. 2014;5:5202.
  107. Rosenstein BS et al. Radiogenomics: radiobiology enters the era of big data and team science. Int. J. Radiat. Oncol. Biol. Phys. 2014;89(4):709–13.
  108. Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA. Cancer J. Clin. 2017;67(1):65–85.
  109. Algazi AP, Grandis JR. Head and neck cancer in 2016: A watershed year for improvements in treatment?. Nat. Rev. Clin. Oncol. 2016;14(2):76–78.
  110. Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development. J. Clin. Oncol. 2015;33(12). doi:10.1200/JCO.2014.58.8848
  111. Morgan M a., Lawrence TS. Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin. Cancer Res. 2015;21(13):2898–2904.
  112. Birzele F et al. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clin. Cancer Res. 2015;(9):1–11.
  113. Gurtner K et al. Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiother. Oncol. 2012;102(3):444–9.
  114. Roelofs E et al. International data-sharing for radiotherapy research: An open-source based infrastructure for multicentric clinical data mining. Radiother. Oncol. 2014;110(2):370–374.